Pateclizumab

• CAT Number: I040387
• CAS Number: 1202526-59-7
• Purity: ≥95%

Pateclizumab(CAT: I040387) is a humanized monoclonal antibody that specifically targets lymphotoxin-α (LTα), a cytokine involved in lymphoid tissue development and chronic inflammation. By blocking LTα’s interaction with the lymphotoxin-β receptor, Pateclizumab disrupts key signaling pathways associated with autoimmune and inflammatory diseases, notably rheumatoid arthritis. This selective inhibition reduces lymphoid neogenesis and inflammatory cell recruitment, offering a novel approach to modulating immune responses. Pateclizumab has been explored in clinical studies for its therapeutic potential and continues to serve as a valuable tool in immunology and autoimmune disease research. Supplied at high purity, it is intended for advanced biomedical and pharmacological studies.